Stock Taper 
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company developing novel HER2/neu-targeted cancer immunotherapies, with its lead candidate GP2 having completed Phase IIb trials to prevent breast cancer recurrence.
GLSI-100 is a Phase III cancer immunotherapy combining GP2 and GM-CSF to prevent breast cancer recurrence in HER2-positive patients, with FDA Fast Track status.
The U.S. Food and Drug Administration (FDA) granted Fast Track designation for GLSI-100, the company's lead immunotherapy product aimed at preventing breast cancer recurrence. This designation is a significant regulatory milestone intended to facilitate the development and expedite the review of drugs that treat serious conditions and fill an unmet medical need, potentially leading to earlier drug approval.
Greenwich LifeSciences announced a strategic plan to build out its internal clinical trial management and operations team for its Phase III FLAMINGO-01 trial. This move is intended to reduce dependency on more costly Clinical Research Organizations (CROs), thereby lowering the company's cash burn rate and increasing efficiency as the trial expands.
Greenwich LifeSciences, Inc. (NASDAQ: GLSI - Get Free Report)'s stock price fell 2.1% during mid-day trading on Friday. The stock traded as low as $16.60 and last traded at $16.98. Approximately 175,415 shares traded hands during mid-day trading, an increase of 57% from the average session volume of 111,705 shares. The stock had previously closed at
Overall rating: C-
| PEER | PRICE | |
|---|---|---|
 IMMX | $9.26 | COMPARE |
 IRD | $4.38 | COMPARE |
 AGEN | $7.56 | COMPARE |
 SRZN | $27.42 | COMPARE |
 HURA | $1.90 | COMPARE |
 SEER | $2.19 | COMPARE |
 CGTX | $0.91 | COMPARE |
 ONCY | $0.55 | COMPARE |
